接受英夫利西单抗主动与被动血药浓度监测的炎症性肠病患者长期结局改善的比较
多中心回顾性研究纳入264例接受英夫利西单抗维持治疗的炎症性肠病患者,主动监测组130例、被动监测组134例,中位随访2.4年。主动监测与治疗失败、IBD相关手术、IBD相关住院、英夫利西单抗抗体及严重输注反应风险降低独立相关。
要点
- 主动监测组较被动监测组治疗失败风险降低(HR 0.16,95%CI 0.09-0.27,P<.001)。
- 主动监测组较被动监测组IBD相关手术风险降低(HR 0.30,95%CI 0.11-0.80,P=.017)。
- 主动监测组较被动监测组IBD相关住院、英夫利西单抗抗体及严重输注反应风险均降低。
核心结论
- 在回顾性分析中,主动监测英夫利西单抗血药浓度与更好的临床结局相关,包括药物持久性更高、IBD相关手术或住院需求更少、英夫利西单抗抗体或严重输注反应风险更低。
研究设计与样本
- 多中心回顾性研究,纳入264例接受英夫利西单抗维持治疗的炎症性肠病患者(其中克罗恩病167例),主动监测组130例、被动监测组134例。
- 监测基于首次英夫利西单抗浓度及英夫利西单抗抗体检测,时间范围为2006年9月至2015年1月,随访至2015年12月,中位随访时间2.4年。
主要发现
- 多因素Cox回归分析显示,与被动监测相比,主动监测与治疗失败风险降低独立相关(HR 0.16;95%CI 0.09-0.27;P<.001)。
- 主动监测与IBD相关手术风险降低独立相关(HR 0.30;95%CI 0.11-0.80;P=.017)。
- 主动监测与IBD相关住院风险降低独立相关(HR 0.16;95%CI 0.07-0.33;P<.001)。
- 主动监测与英夫利西单抗抗体风险降低独立相关(HR 0.25;95%CI 0.07-0.84;P=.025)。
- 主动监测与严重输注反应风险降低独立相关(HR 0.17;95%CI 0.04-0.78;P=.023)。
临床怎么用
- 原文结论指出,主动监测英夫利西单抗血药浓度与更好的临床结局相关,包括药物持久性更高、IBD相关手术或住院需求更少、英夫利西单抗抗体或严重输注反应风险更低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or in patients in clinical remission in which the drug is titrated to a target concentration (proactive drug monitoring). We compared long-term outcomes of patients with IBD undergoing proactive vs reactive monitoring of serum concentrations of infliximab. METHODS: We performed a multicenter, retrospective study of 264 consecutive patients with IBD (167 with Crohn's disease) receiving infliximab maintenance therapy. The subjects received proactive (n = 130) or reactive (n = 134) drug monitoring, based on measurements of first infliximab concentration and antibodies to infliximab, from September 2006 to January 2015; they were followed through December 2015 (median time of 2.4 years). We analyzed time to treatment failure, first IBD-related surgery or hospitalization, serious infusion reaction, and detection of antibodies to infliximab. Treatment failure was defined as drug discontinuation for loss of response or serious adverse event, or need for surgery. RESULTS: Multiple Cox regression analysis independently associated proactive drug monitoring, compared with reactive monitoring, with reduced risk for treatment failure (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.09-0.27; P < .001), IBD-related surgery (HR, 0.30; 95% CI, 0.11-0.80; P = .017), IBD-related hospitalization (HR, 0.16; 95% CI, 0.07-0.33; P < .001), antibodies to infliximab (HR, 0.25; 95% CI, 0.07-0.84; P = .025), and serious infusion reaction (HR, 0.17; 95% CI, 0.04-0.78; P = .023). CONCLUSIONS: In a retrospective analysis of patients with IBD receiving proactive vs reactive monitoring of serum concentration of infliximab, proactive monitoring was associated with better clinical outcomes, including greater drug durability, less need for IBD-related surgery or hospitalization, and lower risk of antibodies to infliximab or serious infusion reactions.
引用
- Papamichael K, Chachu KA, Vajravelu RK, et al. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clin Gastroenterol Hepatol. 2017. PMID: 28365486. doi:10.1016/j.cgh.2017.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。